Combating HIV resistance – focus on darunavir

References

• ArastehKClumeckNPozniakA2005TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trialAids19943715905675
   PubMed Web of Science ®Google Scholar
• BusseKHPenzakSR2007Darunavir: A second-generation protease inhibitorAm J Health Syst Pharm64159360217646561
   PubMed Web of Science ®Google Scholar
• CarterNJKeatingGM2007MaravirocDrugs67227788discussion 2289–90.17927288
   PubMed Web of Science ®Google Scholar
• ClotetBBellosNMolinaJM2007Efficacy and safety of daruna-vir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsLancet36911697817416261
   PubMed Web of Science ®Google Scholar
• ClumeckNChiliadePClotetB2007ARTEMIS – Efficacy and Safety of Lopinavir (BID vs QD) and Darunavir (QD) in Antiretroviral-Naive Patients11th European AIDS ConferenceMadrid, Spain
   Google Scholar
• De MeyerSAzijnHSurlerauxD2005TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolatesAntimicrob Agents Chemother4923142115917527
   PubMed Web of Science ®Google Scholar
• De MeyerSLefebvreEAzijnH2006Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 315th International HIV Drug Resistance WorkshopSitges, Spain
   Google Scholar
• De MeyerSVangeneugdenTvan BaelenB2007Effect of baseline and on-treatment mutations on the antiretroviral activity of darunavir/ ritonavir (DRV/r) and lopinavir/ritonavir (LPV/r): results of a randomised, controlled, phase III study (TITAN)4th International AIDS Society Conference on HIV Pathogenesis, Treatment and PreventionSydney, Australia
   Google Scholar
• De MeyerSVangeneugdenTVan BaelenB2008Resistance profile of darunavir: combined 24-week results from the POWER trialsAIDS Res Hum Retroviruses243798818327986
   PubMed Web of Science ®Google Scholar
• DejesusEOrtizRKhanlouH2007Efficacy and safety of darunavir/ ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at week 48: ARTEMIS47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)Chicago, Illinois
   Google Scholar
• DelaugerreCMathezDPeytavinG2007Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patientsAids211210317502734
   PubMed Web of Science ®Google Scholar
• [DHHS] US Department of Health and Human Services2008Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsDHHS
   Google Scholar
• FlexnerC1998HIV-protease inhibitorsN Engl J Med3381281929562584
   PubMed Web of Science ®Google Scholar
• GhoshAKChapsalBDWeberIT2007Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistanceAcc Chem Res41788617722874
   PubMed Web of Science ®Google Scholar
• GhoshA KSridharPRLeshchenkoS2006Structure-based design of novel HIV-1 protease inhibitors to combat drug resistanceJ Med Chem4952526116913714
   PubMed Web of Science ®Google Scholar
• GrinsztejnBNguyenBYKatlamaC2007Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialLancet3691261917434401
   PubMed Web of Science ®Google Scholar
• GroeschenHM2007Novel HIV treatment approvedAm J Health Syst Pharm64188617823091
   PubMed Web of Science ®Google Scholar
• HallDBSchapiroJBoucherCAB2007Genotypic relationships between tipranavir and darunavir resistance in protease inhibitor experienced patients6th Intl HIV Drug Resistance WorkshopBarbados, West Indies
   Google Scholar
• HammerSMSaagMSSchechterM2006Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society – USA panelTop HIV Med148274317016878
   PubMedGoogle Scholar
• JohnsonVABrun-VezinetFClotetB2007Update of the drug resistance mutations in HIV-1: 2007Top HIV Med151192517720996
   PubMedGoogle Scholar
• KatlamaCEspositoRGatellJM2007Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1Aids2139540217301557
   PubMed Web of Science ®Google Scholar
• KingNMPrabu-JeyabalanMNalivaikaEA2004Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitorJ Virol78120122115479840
   PubMed Web of Science ®Google Scholar
• KohYMatsumiSDasD2007Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerizationJ Biol Chem39287092017635930
   PubMed Web of Science ®Google Scholar
• KohYNakataHMaedaK2003Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitroAntimicrob Agents Chemother473123914506019
   PubMed Web of Science ®Google Scholar
• KovalevskyAYLiuFLeshchenkoS2006aUltra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114J Mol Biol3631617316962136
   PubMed Web of Science ®Google Scholar
• KovalevskyAYTieYLiuF2006bEffectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90MJ Med Chem4913798716480273
   PubMed Web of Science ®Google Scholar
• KuritzkesDR2007HIV resistance: frequency, testing, mechanismsTop HIV Med15150418073450
   PubMedGoogle Scholar
• LazzarinACampbellTClotetB2007Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trialLancet370394817617271
   PubMed Web of Science ®Google Scholar
• MadrugaJVBergerDMcMurchieM2007aEfficacy and safety of darunavirritonavir compared with that of lopinavirritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trialLancet370495817617272
   PubMed Web of Science ®Google Scholar
• MadrugaJVCahnPGrinsztejnB2007bEfficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trialLancet370293817617270
   PubMed Web of Science ®Google Scholar
• MascoliniMBoucherCLarderB2007Key reports from the XV International HIV Drug Resistance Workshop 2006Antivir Ther121314517503758
   PubMed Web of Science ®Google Scholar
• MolinaJMCohenCKatlamaC2007Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3J Acquir Immune Defic Syndr46243117621237
   PubMed Web of Science ®Google Scholar
• PicchioG2006Analyses of susceptibility and cross-resistance between TMC114 and other protease inhibitors among >56,000 routine samples, using linear regression model-based fold change predictionsXV International Drug Resistance WorkshopSitges, Spain
   Google Scholar
• PovedaEde MendozaCMartin-CarboneroL2007Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitorsJ Antimicrob Chemother60885817646201
   PubMed Web of Science ®Google Scholar
• StephensonJ2007Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virusJAMA2971535617426263
   PubMed Web of Science ®Google Scholar
• SurlerauxDLTahriAVerschuerenWG2005Discovery and selection of TMC114, a next generation HIV-1 protease inhibitorJ Med Chem4818132215771427
   PubMed Web of Science ®Google Scholar
• TieYKovalevskyAYBorossP2007Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavirProteins672324217243183
   PubMed Web of Science ®Google Scholar
• TraynorK2007Integrase inhibitor gains FDA approvalAm J Health Syst Pharm64231017989435
   PubMed Web of Science ®Google Scholar
• Vangeneugden2006Impact of optimised background regimen on virological response to TMC114 with low-dose ritonavir in POWER 1, 2 and 3, as measured by the phenotypic susceptibility score15th International HIV Drug Resistance WorkshopSitges, Spain
   Google Scholar
• VermeirenHvan CraenenbroeckEAlenP2007Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modelingJ Virol Methods145475517574687
   PubMed Web of Science ®Google Scholar